Anti-EGFR antibody significantly reduced the percentage of mice with lung nodules more efficiently than rapamycin likely by inhibiting activation of Erk as well as S6 phosphorylation as demonstrated in vitro in LAM/TSC cells. Here, EGFR is linked to lymphangioleiomyomatosis.